<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JCN</journal-id>
<journal-id journal-id-type="hwp">spjcn</journal-id>
<journal-id journal-id-type="nlm-ta">J Child Neurol</journal-id>
<journal-title>Journal of Child Neurology</journal-title>
<issn pub-type="ppub">0883-0738</issn>
<issn pub-type="epub">1708-8283</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0883073812453872</article-id>
<article-id pub-id-type="publisher-id">10.1177_0883073812453872</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Special Issue Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>A Review of Friedreich Ataxia Clinical Trial Results</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Perlman</surname>
<given-names>Susan L.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0883073812453872">1</xref>
<xref ref-type="corresp" rid="corresp1-0883073812453872"/>
</contrib>
<aff id="aff1-0883073812453872"><label>1</label>Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA, USA</aff>
</contrib-group>
<contrib-group content-type="issue">
<contrib contrib-type="editor">
<name>
<surname>Maria</surname>
<given-names>Bernard L.</given-names>
</name>
<degrees>MD, MBA</degrees>
</contrib>
</contrib-group>
<author-notes>
<corresp id="corresp1-0883073812453872">Susan L. Perlman, MD, Department of Neurology, David Geffen School of Medicine at UCLA, 300 UCLA Medical Plaza, Suite B200, Los Angeles, CA 90095, USA Email: <email>sperlman@ucla.edu</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>9</month>
<year>2012</year>
</pub-date>
<volume>27</volume>
<issue>9</issue>
<issue-title>Special Issue: Childhood Ataxia</issue-title>
<fpage>1217</fpage>
<lpage>1222</lpage>
<history>
<date date-type="received">
<day>13</day>
<month>6</month>
<year>2012</year>
</date>
<date date-type="accepted">
<day>13</day>
<month>6</month>
<year>2012</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>There are now 21 agents or classes of therapeutic agents in the Friedreich ataxia research pipeline (http://www.curefa.org/pipeline.html) that have been developed in the 15 years since the discovery of the frataxin gene, with the ongoing characterization of its mutations and the resulting molecular pathology. Twenty-four studies are currently posted on ClinicalTrials.gov. Twenty-seven works discussing the results of clinical trials in Friedreich ataxia have been published. In 2010, 42 public (National Institutes of Health) and private (Friedreich Ataxia Research Alliance, Muscular Dystrophy Association, and National Ataxia Foundation) grants were funded for translational and clinical research in Friedreich ataxia. Millions of dollars from public, private, and industry-based initiatives have been dedicated to research in Friedreich ataxia therapeutics. Despite this vigorous international effort, there is as yet no proven disease-modifying therapy for Friedreich ataxia.</p>
</abstract>
<kwd-group>
<kwd>Friedreich ataxia</kwd>
<kwd>clinical trials</kwd>
<kwd>treatment</kwd>
<kwd>frataxin</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>Friedreich ataxia is an autosomal recessive degenerative disorder characterized by ataxia, areflexia, sensory loss, weakness, scoliosis, and cardiomyopathy. Diabetes mellitus, optic neuropathy, and hearing loss are also seen.<sup>
<xref ref-type="bibr" rid="bibr1-0883073812453872">1</xref>,<xref ref-type="bibr" rid="bibr2-0883073812453872">2</xref>
</sup> Most patients with Friedreich ataxia (97%) have expansions of a GAA repeat in the first intron on both alleles of the gene encoding the mitochondrial protein frataxin,<sup>
<xref ref-type="bibr" rid="bibr2-0883073812453872">2</xref>,<xref ref-type="bibr" rid="bibr3-0883073812453872">3</xref>
</sup> whose expression is reduced in Friedreich ataxia.<sup>
<xref ref-type="bibr" rid="bibr4-0883073812453872">4</xref>
</sup> The size of the GAA repeat expansion inversely correlates with frataxin expression and the age of disease onset.<sup>
<xref ref-type="bibr" rid="bibr3-0883073812453872">3</xref>
</sup> Deficiency of frataxin in cells leads to decreased activities of mitochondrial iron-sulfur cluster–containing enzymes, accumulation of iron in the mitochondrial matrix, increased sensitivity to oxidative stress, and impaired adenosine triphosphate (ATP) production.<sup><xref ref-type="bibr" rid="bibr5-0883073812453872">5</xref><xref ref-type="bibr" rid="bibr6-0883073812453872"/>–<xref ref-type="bibr" rid="bibr7-0883073812453872">7</xref></sup> Targets for disease-modifying drug development have included mitochondrially targeted agents (1) to reduce oxidative stress and free-radical generation, (2) to improve ATP production, (3) to reduce iron accumulation, and (4) to increase frataxin production and the assembly of iron-sulfur clusters.<sup>
<xref ref-type="bibr" rid="bibr8-0883073812453872">8</xref>
</sup> There are now 21 agents or classes of therapeutic agents in the Friedreich ataxia research pipeline (http://www.curefa.org/pipeline.html).</p>
<sec id="section1-0883073812453872" sec-type="methods">
<title>Methods</title>
<sec id="section2-0883073812453872">
<title>Infrastructure for Clinical Trials</title>
<p>For a group of clinical researchers to move a disease forward into the era of clinical trials, disease mechanisms must be understood, candidate drugs must be identified, the natural history baseline must be documented, rating scales and quality of life measures must be validated, biomarkers must be developed, clinical research centers must be established, a patient registry must be available, and a database must be operational. Future resources might include telemedicine, electronic monitoring, and international collaborations.</p>
<p>In Friedreich ataxia, understanding of disease mechanisms and concurrent identification of candidate drugs have moved ahead steadily since 1996. Collaborative international efforts have resulted in the validation of 3 rating scales (International Cooperative Ataxia Rating Scale [ICARS], Friedreich Ataxia Rating Scale [FARS], and Scale for the Assessment and Rating of Ataxia [SARA]<sup>
<xref ref-type="bibr" rid="bibr9-0883073812453872">9</xref>
</sup>), the completion of 7 natural history studies,<sup><xref ref-type="bibr" rid="bibr10-0883073812453872">10</xref><xref ref-type="bibr" rid="bibr11-0883073812453872"/><xref ref-type="bibr" rid="bibr12-0883073812453872"/><xref ref-type="bibr" rid="bibr13-0883073812453872"/><xref ref-type="bibr" rid="bibr14-0883073812453872"/><xref ref-type="bibr" rid="bibr15-0883073812453872"/>–<xref ref-type="bibr" rid="bibr16-0883073812453872">16</xref></sup> and the search for biomarkers,<sup><xref ref-type="bibr" rid="bibr17-0883073812453872">17</xref><xref ref-type="bibr" rid="bibr18-0883073812453872"/>–<xref ref-type="bibr" rid="bibr19-0883073812453872">19</xref></sup> all for use in the design of clinical trials. A network of clinical research centers has been set up in the United States, Australia, and Europe (<ext-link ext-link-type="uri" xlink:href="http://www.curefa.org/network.html">http://www.curefa.org/network.html</ext-link>; <ext-link ext-link-type="uri" xlink:href="http://www.eurosca.org/index.html">http://www.eurosca.org/index.html</ext-link>), with attendant registries (http://www.curefa.org/registry.html; http://www.fara.org.au/?page_id=119; and http://www.orpha.net/orphacom/cahiers/docs/GB/Registries.pdf).</p>
<p>However, Friedreich ataxia is a rare disease, affecting just 1 in 50 000 individuals. Success in moving forward with clinical trials ultimately depends on encouraging every Friedreich ataxia patient to participate in clinical trials and in ensuring that every researcher designing a clinical trial makes it accessible to all FRDA patients.</p>
</sec>
<sec id="section3-0883073812453872">
<title>Disease-Modifying Agents in Current Clinical Trials</title>
<p>It is estimated that the process from the first good idea about developing a new drug through its final United States Food and Drug Administration (FDA) approval can take 15 years and millions of dollars (<xref ref-type="table" rid="table1-0883073812453872">Tables 1</xref> and <xref ref-type="table" rid="table2-0883073812453872">2</xref>). Discovery, with clinicians and scientists working out the cause of the disease, the pathophysiological “dominoes” that fall over, and the potential candidate drugs can cost from $25 000 to $80 000 per year over many years.</p>
<table-wrap id="table1-0883073812453872" position="float">
<label>Table 1.</label>
<caption>
<p>Types of Clinical Trials</p>
</caption>
<graphic alternate-form-of="table1-0883073812453872" xlink:href="10.1177_0883073812453872-table1.tif"/>
<table>
<thead>
<tr>
<th>Type</th>
<th>No. of patients</th>
<th>Length </th>
<th>Aim of study</th>
</tr>
</thead>
<tbody>
<tr>
<td>N of 1</td>
<td>1</td>
<td>Ongoing</td>
<td>Do I get better on this drug?</td>
</tr>
<tr>
<td>Pilot</td>
<td>Up to 20 patients; all get the drug</td>
<td>Weeks to months</td>
<td>Is a larger study worth doing? Will there be problems?</td>
</tr>
<tr>
<td>Phase 1</td>
<td>20-80 normals or patients, in groups of 3</td>
<td>2 years</td>
<td>Escalating doses to learn side effects, safety, and best dose</td>
</tr>
<tr>
<td>Phase 2</td>
<td>20-300 patients; control and drug groups</td>
<td>2 years</td>
<td>To assess the potential for good effects as well as side effects; control group may be on placebo</td>
</tr>
<tr>
<td>Phase 3</td>
<td>300-3000 patients; control and drug groups</td>
<td>3-5 years</td>
<td>To prove efficacy (the drug works); may include crossover design or open extension trial</td>
</tr>
<tr>
<td>Phase 4</td>
<td>Hundreds to thousands; open drug use</td>
<td>Ongoing</td>
<td>To find out more about the effects of a Food and Drug Administration–approved drug</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="table2-0883073812453872" position="float">
<label>Table 2.</label>
<caption>
<p>Current Clinical Trials Posted at ClinicalTrials.gov</p>
</caption>
<graphic alternate-form-of="table2-0883073812453872" xlink:href="10.1177_0883073812453872-table2.tif"/>
<table>
<tbody>
<tr>
<td>
<bold>13 completed studies (12 drug trials, 1 quality of life study)</bold>
</td>
</tr>
<tr>
<td>
<list list-type="bullet">
<list-item>
<p>Safety Study of Idebenone to Treat Friedreich’s Ataxia (4/2006, 1 publication)</p>
</list-item>
<list-item>
<p>Phase 1B Trial of Idebenone to Treat Patients With Friedreich’s Ataxia (4/2006, 1 publication)</p>
</list-item>
<list-item>
<p>Idebenone to Treat Friedreich’s Ataxia (12/2007, 2 publications)</p>
</list-item>
<list-item>
<p>A Study of Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich’s Ataxia (FRDA) IONIA (4/2009, 2 publications)</p>
</list-item>
<list-item>
<p>Study to Assess the Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich’s Ataxia MICONOS (1/2010)</p>
</list-item>
<list-item>
<p>Study to Assess the Safety and Tolerability of Idebenone in the Treatment of Friedreich’s Ataxia IONIA-E (5/2010, 1 publication)</p>
</list-item>
<list-item>
<p>Iron-Chelating Therapy and Friedreich Ataxia (3/2008, 1 publication)<sup><xref ref-type="table-fn" rid="table-fn1-0883073812453872">a</xref></sup>
</p>
</list-item>
<list-item>
<p>A Study Investigating the Safety and Tolerability of Deferiprone in Patients With Friedreich’s Ataxia (7/2009)</p>
</list-item>
<list-item>
<p>A Study Investigating the Long-term Safety and Efficacy of Deferiprone in Patients With Friedreich’s Ataxia (3/2011)<sup><xref ref-type="table-fn" rid="table-fn1-0883073812453872">a</xref></sup>
</p>
</list-item>
<list-item>
<p>Safety and Efficacy Study of A0001 in Subjects With Friedreich’s Ataxia (3/2011)</p>
</list-item>
<list-item>
<p>Efficacy of Epoetin Alfa in Patients With Friedreich’s Ataxia (6/2009, 1 publication)<sup><xref ref-type="table-fn" rid="table-fn1-0883073812453872">a</xref></sup>
</p>
</list-item>
<list-item>
<p>Safety Study of Carbamylated Erythropoietin to Treat Patients With Friedreich Ataxia (4/2011)</p>
</list-item>
<list-item>
<p>Transitional Life Events in Patients With Friedreich’s Ataxia: Implications for Genetic Counseling (1/2004, 1 publication)</p>
</list-item>
</list>
</td>
</tr>
<tr>
<td>
<bold>1 terminated study</bold>
<list list-type="bullet">
<list-item>
<p>Pilot Study of Varenicline (Chantix<sup>®</sup>) in the Treatment of Friedreich’s Ataxia (4/2010)</p>
</list-item>
</list>
</td>
</tr>
<tr>
<td>
<bold>2 active studies, not recruiting</bold>
<list list-type="bullet">
<list-item>
<p>Effect of Pioglitazone Administered to Patients With Friedreich’s Ataxia: Proof of Concept</p>
</list-item>
<list-item>
<p>Long-term Safety and Tolerability of Idebenone in Friedreich’s Ataxia Patients (MICONOS Ext)</p>
</list-item>
</list>
</td>
</tr>
<tr>
<td>
<bold>6 recruiting studies</bold>
<list list-type="bullet">
<list-item>
<p>Safety and Efficacy of Intravenous Immune Globulin in Treating Friedreich’s Ataxia and SCA3<sup><xref ref-type="table-fn" rid="table-fn1-0883073812453872">a</xref></sup>
</p>
</list-item>
<list-item>
<p>A Study of Resveratrol as Treatment for Friedreich Ataxia<sup><xref ref-type="table-fn" rid="table-fn1-0883073812453872">a</xref></sup>
</p>
</list-item>
<list-item>
<p>Efficacy of EGb761 in Patients Suffering From Friedreich Ataxia</p>
</list-item>
<list-item>
<p>Patient-Reported Outcomes in Friedreich’s Ataxia Patients</p>
</list-item>
<list-item>
<p>After Withdrawal From Treatment With Idebenone</p>
</list-item>
<list-item>
<p>Efficacy of Riluzole in Hereditary Cerebellar Ataxia</p>
</list-item>
<list-item>
<p>EPI-743 for Mitochondrial Respiratory Chain Diseases<sup><xref ref-type="table-fn" rid="table-fn1-0883073812453872">a</xref></sup>
</p>
</list-item>
</list>
</td>
</tr>
<tr>
<td>
<bold>Posted on FARA Web site (www.curefa.org)</bold>
<list list-type="bullet">
<list-item>
<p>Friedreich ataxia patient registry</p>
</list-item>
<list-item>
<p>Friedreich ataxia clinical outcome measures study (multicenter, natural history study)</p>
</list-item>
<list-item>
<p>Friedreich ataxia biomarkers study (University of South Florida)</p>
</list-item>
<list-item>
<p>Cardiac magnetic resonance imaging study (Ohio State University)</p>
</list-item>
<list-item>
<p>Auditory, speech, and vestibular abilities (Alfred I. duPont Hospital for Children)</p>
</list-item>
<list-item>
<p>Newborn screening project (Mayo Clinic)</p>
</list-item>
<list-item>
<p>Autopsy and tissue donation program (VA Medical Center, Albany, NY)</p>
</list-item>
<list-item>
<p>Smaller studies at individual institutions (MRS, OCT, other biomarkers) </p>
</list-item>
</list>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0883073812453872">
<p>
<sup>a</sup> An open-label study.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Preclinical testing in test tube and animal studies typically costs $100 000 per year for at least 2 years. Phase I and phase II studies can run from $500 000 to $700 000 per year for 4 years. It is often $2 million to $4 million just to get to this point. The final phase III studies require an additional $4 million to $5 million ($10 000/subject) to be raised to bring the drug to FDA approval. This cannot be achieved without solid partnership between public, private, and ultimately industry resources.</p>
<p>Disease-modifying strategies in Friedreich ataxia include gene/protein replacement therapy, pharmacological enhancement of frataxin expression (eg, with the use of erythropoietin<sup><xref ref-type="bibr" rid="bibr20-0883073812453872">20</xref><xref ref-type="bibr" rid="bibr21-0883073812453872"/><xref ref-type="bibr" rid="bibr22-0883073812453872"/><xref ref-type="bibr" rid="bibr23-0883073812453872"/>–<xref ref-type="bibr" rid="bibr24-0883073812453872">24</xref></sup>), restitution of mitochondrial function, restoration of iron homeostasis, neuroprotection by trophic factors, and lipid-soluble antioxidant therapy (despite some uncertainty about the size of the role of oxidative stress<sup>
<xref ref-type="bibr" rid="bibr25-0883073812453872">25</xref>
</sup>).<sup>
<xref ref-type="bibr" rid="bibr26-0883073812453872">26</xref>
</sup> High-throughput screening techniques are speeding up the identification of candidate drugs in all these areas.<sup>
<xref ref-type="bibr" rid="bibr27-0883073812453872">27</xref>
</sup>
</p>
</sec>
</sec>
<sec id="section4-0883073812453872">
<title>Results</title>
<p>At the head of the line in drug development has been the class of lipid-soluble antioxidants because they have a basic science and animal study rationale to work, have a good risk/benefit ratio, and have a number of agents already available.<sup>
<xref ref-type="bibr" rid="bibr28-0883073812453872">28</xref>
</sup> These antioxidant drug trials have still been faced with the complication of the cost of seeing a drug through to FDA approval, when its marketability may be small and restricted to a few rare diseases.</p>
<p>Vitamin E, coenzyme Q10, and idebenone (2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone), a synthetic analog of coenzyme Q10 with potent antioxidant activity and the ability to facilitate the flux of electrons along the mitochondrial electron transport chain, increasing the production of ATP,<sup>
<xref ref-type="bibr" rid="bibr29-0883073812453872">29</xref>
</sup> have been extensively studied (<xref ref-type="table" rid="table3-0883073812453872">Tables 3</xref> and <xref ref-type="table" rid="table4-0883073812453872">4</xref>), and a number of other “designer” antioxidants are in the pipeline (http://www.curefa.org/pipeline.html).</p>
<table-wrap id="table3-0883073812453872" position="float">
<label>Table 3.</label>
<caption>
<p>Lipid-Soluble Antioxidant Trials</p>
</caption>
<graphic alternate-form-of="table3-0883073812453872" xlink:href="10.1177_0883073812453872-table3.tif"/>
<table>
<thead>
<tr>
<th>Study</th>
<th>Trial design</th>
<th>Trial length</th>
<th>No. of patients</th>
<th>Outcome measures</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Artuch et al<sup>
<xref ref-type="bibr" rid="bibr42-0883073812453872">42</xref>
</sup>
</td>
<td>Open label; idebenone 5 mg/kg/d</td>
<td>1 year</td>
<td>9 patients aged 11-19 years</td>
<td>ICARS scores, neurophysiological investigations, and echocardiographic measurements</td>
<td>Cerebellar improvement was notable in mild patients after the first 3 months of therapy (<italic>P</italic> = .017). There was no cardiac benefit.</td>
</tr>
<tr>
<td>Hart et al<sup>
<xref ref-type="bibr" rid="bibr30-0883073812453872">30</xref>
</sup>
</td>
<td>Open label; coenzyme Q10 400 mg/d with vitamin E 2100 IU/d</td>
<td>47 months</td>
<td>10 patients</td>
<td>Echocardiography, ICARS, and cardiac and skeletal muscle bioenergetics as assessed using 31P magnetic resonance spectroscopy</td>
<td>Sustained improvement in mitochondrial energy synthesis that was associated with a slowing of the progression of certain clinical features compared with natural history data and a significant improvement in cardiac function.</td>
</tr>
<tr>
<td>Cooper et al<sup>
<xref ref-type="bibr" rid="bibr31-0883073812453872">31</xref>
</sup>
</td>
<td>Randomized, double blind; 2 arms: high dose (coQ10/E) and low dose (coQ10/E)</td>
<td>2 years</td>
<td>25 patients in each arm</td>
<td>ICARS</td>
<td>When compared to cross-sectional data, 49% of all patients demonstrated improved ICARS scores. This responder group had significantly lower baseline serum CoQ(10) levels.</td>
</tr>
<tr>
<td>Hausse et al<sup>
<xref ref-type="bibr" rid="bibr32-0883073812453872">32</xref>
</sup>
</td>
<td>Open label; idebenone 5 mg/kg/d</td>
<td>6 months</td>
<td>38 patients aged 4-22 years</td>
<td>Echocardiography</td>
<td>Reduction in left ventricular mass of more than 20% in about half the patients (<italic>P</italic> &lt; .001).</td>
</tr>
<tr>
<td>Mariotti et al<sup>
<xref ref-type="bibr" rid="bibr33-0883073812453872">33</xref>
</sup>
</td>
<td>Randomized, double blind, placebo controlled; idebenone 5 mg/kg/d</td>
<td>1 year</td>
<td>29 patients</td>
<td>ICARS, echocardiography</td>
<td>Idebenone treatment had no serious side effects and was associated with persisting, although moderate, effects on echographic indexes of heart hypertrophy. There was no effect on ICARS.</td>
</tr>
<tr>
<td>Buyse et al<sup>
<xref ref-type="bibr" rid="bibr34-0883073812453872">34</xref>
</sup>
</td>
<td>Open label; idebenone 5 mg/kg/d</td>
<td>1 year</td>
<td>8 patients aged 8-27 years</td>
<td>Cooperative Ataxia Group rating scale, echocardiography</td>
<td>Significant reduction of cardiac hypertrophy in 6 of 8 patients. Cardiac strain and strain rate imaging showed that the reduction of hypertrophy was preceded by an early and linear improvement in cardiac function. There was no change in neurological function.</td>
</tr>
<tr>
<td>Pineda et al<sup>
<xref ref-type="bibr" rid="bibr35-0883073812453872">35</xref>
</sup> </td>
<td>Open label; idebenone 5-20 mg/kg/d</td>
<td>3-5 years</td>
<td>10 patients aged 8-17 years; 14 patients aged 18-46 years</td>
<td>ICARS, echocardiography</td>
<td>Longer-term idebenone treatment prevented the progression of cardiomyopathy in both pediatric and adult patients, whereas its stabilizing effect on neurological dysfunction was present only in the pediatric population, mainly before puberty.</td>
</tr>
<tr>
<td>Di Prospero et al<sup>
<xref ref-type="bibr" rid="bibr36-0883073812453872">36</xref>,<xref ref-type="bibr" rid="bibr37-0883073812453872">37</xref>
</sup> and Drinkard et al<sup>
<xref ref-type="bibr" rid="bibr43-0883073812453872">43</xref>
</sup>
</td>
<td>Randomized, double blind, placebo controlled, phase II; idebenone at 3 dose levels: 5 mg/kg/d, 15 mg/kg/d, and 45 mg/kg/d</td>
<td>6 months</td>
<td>48 patients aged 9-17 years</td>
<td>ICARS, FARS, and a survey of ADL; exercise capacity: peak oxygen consumption per unit time (peak VO<sub>2</sub>) and peak work rate</td>
<td>Treatment with higher doses of idebenone was generally well tolerated and associated with improvement in neurological function (ICARS) and ADL in patients, especially those who were still ambulatory (Bonferroni, <italic>P</italic> = .03). There was no change in exercise capacity.</td>
</tr>
<tr>
<td>Lynch et al<sup>
<xref ref-type="bibr" rid="bibr38-0883073812453872">38</xref>
</sup> and Lagedrost et al<sup>
<xref ref-type="bibr" rid="bibr39-0883073812453872">39</xref>
</sup>
</td>
<td>Randomized, double blind, placebo controlled, phase III; idebenone at 2 dose levels: 15-25 mg/kg/d and 25-45 mg/kg/d</td>
<td>6 months</td>
<td>70 patients aged 8-17 years; ambulatory</td>
<td>ICARS, FARS, instrumental measures, and a survey of ADL; echocardiography</td>
<td>Idebenone did not significantly alter neurological function during the 6-month study. Idebenone did not decrease left ventricular hypertrophy or improve cardiac function during the 6-month study.</td>
</tr>
<tr>
<td>Meier et al<sup>
<xref ref-type="bibr" rid="bibr40-0883073812453872">40</xref>
</sup> </td>
<td>Open label, extension; idebenone at 25-45 mg/kg/d (1350/2250 mg/d)</td>
<td>1 year</td>
<td>68 patients who had completed the phase III study</td>
<td>ICARS, FARS, instrumental measures, and a survey of ADL </td>
<td>The findings of the open-label IONIA-E study combined with the double-blind IONIA study indicate that idebenone at the high dose of 1350/2250 mg/d can offer a therapeutic benefit to pediatric Friedreich ataxia patients by stabilizing the overall neurological function and improving fine motor skills and speech (ICARS, <italic>P</italic> = .014).</td>
</tr>
<tr>
<td>Velasco-Sanchez et al<sup>
<xref ref-type="bibr" rid="bibr44-0883073812453872">44</xref>
</sup>
</td>
<td>Open label; idebenone 20 mg/kg/d with deferiprone 20 mg/kg/d</td>
<td>11 months</td>
<td>20 patients</td>
<td>ICARS scores, echocardiographic measurements, and magnetic resonance imaging techniques to assess brain iron deposits in the dentate nucleus</td>
<td>Stabilizing effect in neurological dysfunctions due to an improvement in the kinetic functions (<italic>P</italic> = .015), with a worsening of gait and posture scores. Heart hypertrophy parameters (<italic>P</italic> = .04) and iron deposits in the dentate nucleus (<italic>P</italic> = .007) improved significantly. Combined therapy was well tolerated with mild side effects, apart from the risk of neutropenia and progressive reduction of plasma iron parameters.</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-0883073812453872">
<p>ICARS, International Cooperative Ataxia Rating Scale; FARS, Friedreich Ataxia Rating Scale; ADL, activities of daily living.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table4-0883073812453872" position="float">
<label>Table 4.</label>
<caption>
<p>Pharmacological Restitution of Mitochondrial Function and Other Antioxidant Strategies in the Pipeline</p>
</caption>
<graphic alternate-form-of="table4-0883073812453872" xlink:href="10.1177_0883073812453872-table4.tif"/>
<table>
<tbody>
<tr>
<td>
<bold>A0001:</bold> a designer antioxidant/metabolic stimulator. A phase I study in healthy volunteers was conducted in July 2008. The drug was well tolerated by patients, and no serious adverse events were reported. There was a dose-dependent increase in exposure approaching the steady state within 2 to 4 days following repeat dosing, and a maximum tolerated dose was established. A phase II study (placebo, low dose, and high dose) in January 2010 looked at various functional and biochemical measures and patient/clinician-rated scales. Results showed that measures of balance and coordination were significantly better in the group of patients given high doses of EPI-A0001 as well as the group receiving lose doses of the drug in comparison to the placebo group. There were no differences in rates of adverse side effects between the placebo group and each of the drug-treated groups. <bold>EPI-743:</bold> another designer antioxidant/metabolic stimulator. There are no results yet in phase II. <bold>Egb-761:</bold> an extract of <italic>Ginkgo biloba</italic> leaves that has antioxidant properties as a free-radical scavenger. There are no results yet in phase II. <bold>L-carnitine and creatine: </bold>examined in a randomized, placebo-controlled, crossover trial using 31P magnetic resonance spectroscopy to measure improved oxidative phosphorylation and phosphocreatine recovery. No effect was seen with creatine, but there was a promising effect with L-carnitine.<sup>
<xref ref-type="bibr" rid="bibr45-0883073812453872">45</xref>
</sup> <bold>OX1:</bold> (indole-3-propionic acid) naturally occurring small molecular weight drug compound that prevents oxidative stress by a combination of hydroxyl-radical-scavenging activity and metal chelation. Phase I studies in healthy adults were completed in 2010. The drug was found to be safe and well tolerated, and the pharmacokinetics revealed that the drug was rapidly absorbed and distributed in the body after oral administration. <bold>Pioglitazone: </bold>a drug of the thiazolidinedione class, originally developed to reduce insulin resistance in type 2 diabetes mellitus, is a nuclear receptor peroxisome proliferator–activated receptor gamma (PPARγ) that when activated robustly suppresses inflammation as well as expression of cytokines and other inflammatory mediators associated with activated microglia. It is also a mitochondrial stimulator. There are no results yet in phase III. An increased risk of bladder cancer is associated with this drug. <bold>Resveratrol:</bold> can act as an antioxidant/neuroprotective agent. There are no results yet in phase I/II. It can also act to enhance frataxin expression.</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>An ongoing open trial of vitamin E (2100 IU/d) plus coenzyme Q10 (400 mg/d) showed improvement in cardiac and skeletal muscle bioenergetics and changes in the total ICARS score, but posture, gait, and hand dexterity subscores progressed as predicted by natural history data.<sup>
<xref ref-type="bibr" rid="bibr30-0883073812453872">30</xref>
</sup> A high proportion of Friedreich ataxia patients were found to have a decreased serum coenzyme Q10 level, which was the best predictor of a positive clinical response to coenzyme Q10/vitamin E therapy.<sup>
<xref ref-type="bibr" rid="bibr31-0883073812453872">31</xref>
</sup>
</p>
<p>Early pilot studies of low-dose idebenone suggested cardiac but not neurological benefit.<sup>
<xref ref-type="bibr" rid="bibr32-0883073812453872">32</xref><xref ref-type="bibr" rid="bibr33-0883073812453872"/>–<xref ref-type="bibr" rid="bibr34-0883073812453872">34</xref>
</sup> However, new questions were raised: Does echocardiographic evidence of reduced left ventricular hypertrophy indicate cardiac benefit? How does one measure cardiac benefit?</p>
<p>One longer term, open-label study showed neither cardiac nor neurological improvement but suggested cardiac stabilization and, in younger patients, neurological stabilization, suggesting that the age at which idebenone treatment is initiated may be an important factor in the effectiveness of the therapy.<sup>
<xref ref-type="bibr" rid="bibr35-0883073812453872">35</xref>
</sup>
</p>
<p>The phase II idebenone study examined a possible functional measure to support the cardiac benefits of idebenone, but the results were not significant.<sup>
<xref ref-type="bibr" rid="bibr36-0883073812453872">36</xref>,<xref ref-type="bibr" rid="bibr37-0883073812453872">37</xref>
</sup> Apparent neurological benefits warranted moving on to a phase III study in the United States (IONIA) and Europe (MICONOS). Canada went ahead and gave conditional approval for prescribing idebenone (Catena) on the basis of the phase II study results; however, the phase III American and European studies unfortunately did not confirm neurological or cardiac benefits.<sup>
<xref ref-type="bibr" rid="bibr38-0883073812453872">38</xref>,<xref ref-type="bibr" rid="bibr39-0883073812453872">39</xref>
</sup> The open-label extension study of the American cohort (IONIA-E)<sup>
<xref ref-type="bibr" rid="bibr40-0883073812453872">40</xref></sup> indicated that idebenone at a dose of 1350/2250 mg/d might offer a therapeutic benefit to pediatric Friedreich ataxia patients by stabilizing the overall neurological function and improving fine motor skills and speech. A similar open-label extension study in the European cohort (MICONOS-E) is still under analysis.</p>
<p>A blinded idebenone withdrawal study in England is currently recruiting, with the hypothesis that if people did not get better when they were put on idebenone, perhaps they would get worse when taken off it (Patient Reported Outcomes in Friedreich’s Ataxia Patients After Withdrawal From Treatment With Idebenone [PROTI]: NCT01303406).</p>
<p>To date, there are no consistent, statistically significant benefits in the use of lipid-soluble antioxidant therapy in patients with symptomatic Friedreich Ataxia.</p>
</sec>
<sec id="section5-0883073812453872">
<title>Discussion</title>
<p>The lack of statistical significance in clinical trials to date indicates that more specific and potent candidate drugs, more sensitive clinical measures and biomarkers, and better powered clinical trial design are still needed. Patients and families will, however, continue to utilize available antioxidant supplements and off-label agents<sup><xref ref-type="bibr" rid="bibr41-0883073812453872">41</xref></sup> until truly disease-modifying therapies are made available. Because of this, nonprescription antioxidant use represents a major confounder to formal trials of existing and novel agents for Friedreich ataxia. Additional questions raised include the following: Can a study ethically deny patient use of lipid-soluble antioxidants when there is a chance of spending 6 to 12 months on a placebo?</p>
<p>And despite the frustration that many patients and families now feel, they remain the best allies and continue to be highly motivated to participate in clinical trials, despite the inherent sacrifices in time, money, and privacy that these trials can require. As clinical researchers, we owe it to them to keep them informed and to bring together the most robust science, the best funding strategies, and the most reasonable regulatory requirements in a timely fashion to ultimately deliver a cure for Friedreich ataxia.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>The author thanks the National Institutes of Health (NINDS and ORD), the National Ataxia Foundation, the Child Neurology Society, the Department of Pediatrics at the Medical College of Georgia, and the Collaborative Clinical Research Network for Friedreich’s Ataxia for their support of this presentation at the 2011 Neurobiology of Disease in Children Symposium in Savannah, Georgia.</p>
</ack>
<fn-group>
<fn fn-type="conflict" id="fn1-0883073812453872">
<label>Declaration of Conflicting Interests</label>
<p>The author declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn2-0883073812453872">
<label>Funding</label>
<p>The author disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: research grant funding from Edison Pharmaceuticals and Santhera Pharmaceuticals for the purpose of conduct of clinical trials in Friedreich ataxia. None provided support for the preparation of this article.</p>
</fn>
<fn fn-type="other" id="fn3-0883073812453872">
<label>Ethical Approval</label>
<p>Clinical trial results presented were obtained under the institutional review board/ethics board supervision of the institutions where the trials were conducted.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0883073812453872">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harding</surname>
<given-names>AE</given-names>
</name>
</person-group>. <article-title>Friedreich’s ataxia: a clinical and genetic study of 90 families with an analysis of early diagnostic criteria and intrafamilial clustering of clinical features</article-title>. <source>Brain</source>. <year>1981</year>;<volume>104</volume>(<issue>3</issue>):<fpage>589</fpage>–<lpage>620</lpage>.</citation>
</ref>
<ref id="bibr2-0883073812453872">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schulz</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Boesch</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Burk</surname>
<given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>Diagnosis and treatment of Friedreich ataxia: a European perspective</article-title>. <source>Nat Rev Neurol</source>. <year>2009</year>;<volume>5</volume>(<issue>4</issue>):<fpage>222</fpage>–<lpage>234</lpage>.</citation>
</ref>
<ref id="bibr3-0883073812453872">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Durr</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Cossee</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Agid</surname>
<given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>Clinical and genetic abnormalities in patients with Friedreich’s ataxia</article-title>. <source>N Engl J Med</source>. <year>1996</year>;<volume>335</volume>(<issue>16</issue>):<fpage>1169</fpage>–<lpage>1175</lpage>.</citation>
</ref>
<ref id="bibr4-0883073812453872">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Campuzano</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Montermini</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Lutz</surname>
<given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes</article-title>. <source>Hum Mol Genet</source>. <year>1997</year>;<volume>6</volume>(<issue>11</issue>):<fpage>1771</fpage>–<lpage>1780</lpage>.</citation>
</ref>
<ref id="bibr5-0883073812453872">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rotig</surname>
<given-names>A</given-names>
</name>
<name>
<surname>de Lonlay</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Chretien</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia</article-title>. <source>Nat Genet</source>. <year>1997</year>;<volume>17</volume>(<issue>2</issue>):<fpage>215</fpage>–<lpage>217</lpage>.</citation>
</ref>
<ref id="bibr6-0883073812453872">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lodi</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Bradley</surname>
<given-names>JL</given-names>
</name>
<etal/>
</person-group>. <article-title>Deficit of in vivo mitochondrial ATP production in patients with Friedreich ataxia</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>1999</year>;<volume>96</volume>(<issue>20</issue>):<fpage>11492</fpage>–<lpage>11495</lpage>.</citation>
</ref>
<ref id="bibr7-0883073812453872">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Delatycki</surname>
<given-names>MB</given-names>
</name>
<name>
<surname>Camakaris</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Brooks</surname>
<given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Direct evidence that mitochondrial iron accumulation occurs in Friedreich ataxia</article-title>. <source>Ann Neurol</source>. <year>1999</year>;<volume>45</volume>(<issue>5</issue>):<fpage>673</fpage>–<lpage>675</lpage>.</citation>
</ref>
<ref id="bibr8-0883073812453872">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tsou</surname>
<given-names>AY</given-names>
</name>
<name>
<surname>Friedman</surname>
<given-names>LS</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>RB</given-names>
</name>
<name>
<surname>Lynch</surname>
<given-names>DR</given-names>
</name>
</person-group>. <article-title>Pharmacotherapy for Friedreich ataxia</article-title>. <source>CNS Drugs</source>. <year>2009</year>;<volume>23</volume>(<issue>3</issue>):<fpage>213</fpage>–<lpage>223</lpage>.</citation>
</ref>
<ref id="bibr9-0883073812453872">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Burk</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Malzig</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Wolf</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Comparison of three clinical rating scales in Friedreich ataxia (FRDA)</article-title>. <source>Mov Disord</source>. <year>2009</year>;<volume>24</volume>(<issue>12</issue>):<fpage>1779</fpage>–<lpage>1784</lpage>.</citation>
</ref>
<ref id="bibr10-0883073812453872">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Klockgether</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ludtke</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Kramer</surname>
<given-names>B</given-names>
</name>
<etal/>
</person-group>. <article-title>The natural history of degenerative ataxia: a retrospective study in 466 patients</article-title>. <source>Brain</source>. <year>1998</year>;<volume>121</volume>(<issue>Pt 4</issue>):<fpage>589</fpage>–<lpage>600</lpage>.</citation>
</ref>
<ref id="bibr11-0883073812453872">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fahey</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Corben</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Collins</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Churchyard</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Delatycki</surname>
<given-names>MB</given-names>
</name>
</person-group>. <article-title>How is disease progress in Friedreich’s ataxia best measured? A study of four rating scales</article-title>. <source>J Neurol Neurosurg Psychiatry</source>. <year>2007</year>;<volume>78</volume>(<issue>4</issue>):<fpage>411</fpage>–<lpage>413</lpage>.</citation>
</ref>
<ref id="bibr12-0883073812453872">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wilson</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Fahey</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Corben</surname>
<given-names>LA</given-names>
</name>
<etal/>
</person-group>. <article-title>Quality of life in Friedreich ataxia: what clinical, social and demographic factors are important?</article-title> <source>Eur J Neurol</source>. <year>2007</year>;<volume>14</volume>(<issue>9</issue>):<fpage>1040</fpage>–<lpage>1047</lpage>.</citation>
</ref>
<ref id="bibr13-0883073812453872">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lynch</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Farmer</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Tsou</surname>
<given-names>AY</given-names>
</name>
<etal/>
</person-group>. <article-title>Measuring Friedreich ataxia: complementary features of examination and performance measures</article-title>. <source>Neurology</source>. <year>2006</year>;<volume>66</volume>(<issue>11</issue>):<fpage>1711</fpage>–<lpage>1716</lpage>.</citation>
</ref>
<ref id="bibr14-0883073812453872">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Epstein</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Farmer</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Tsou</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Health related quality of life measures in Friedreich ataxia</article-title>. <source>J Neurol Sci</source>. <year>2008</year>;<volume>272</volume>(<issue>1-2</issue>):<fpage>123</fpage>–<lpage>128</lpage>.</citation>
</ref>
<ref id="bibr15-0883073812453872">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Friedman</surname>
<given-names>LS</given-names>
</name>
<name>
<surname>Farmer</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Perlman</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Measuring the rate of progression in Friedreich ataxia: implications for clinical trial design</article-title>. <source>Mov Disord</source>. <year>2010</year>;<volume>25</volume>(<issue>4</issue>):<fpage>426</fpage>–<lpage>432</lpage>.</citation>
</ref>
<ref id="bibr16-0883073812453872">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Paulsen</surname>
<given-names>EK</given-names>
</name>
<name>
<surname>Friedman</surname>
<given-names>LS</given-names>
</name>
<name>
<surname>Myers</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Lynch</surname>
<given-names>DR</given-names>
</name>
</person-group>. <article-title>Health-related quality of life in children with Friedreich ataxia</article-title>. <source>Pediatr Neurol</source>. <year>2010</year>;<volume>42</volume>(<issue>5</issue>):<fpage>335</fpage>–<lpage>337</lpage>.</citation>
</ref>
<ref id="bibr17-0883073812453872">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Coppola</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Burnett</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Perlman</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>A gene expression phenotype in lymphocytes from Friedreich ataxia patients</article-title>. <source>Ann Neurol</source>. <year>2011</year>;<volume>70</volume>(<issue>5</issue>):<fpage>790</fpage>–<lpage>804</lpage>.</citation>
</ref>
<ref id="bibr18-0883073812453872">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schapira</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lodi</surname>
<given-names>R</given-names>
</name>
</person-group>. <article-title>Assessment of in vitro and in vivo mitochondrial function in Friedreich’s ataxia and Huntington’s disease</article-title>. <source>Methods Mol Biol</source>. <year>2004</year>;<volume>277</volume>:<fpage>293</fpage>–<lpage>307</lpage>.</citation>
</ref>
<ref id="bibr19-0883073812453872">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Franca</surname>
<given-names>MC</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>D’Abreu</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Yasuda</surname>
<given-names>CL</given-names>
</name>
<etal/>
</person-group>. <article-title>A combined voxel-based morphometry and 1H-MRS study in patients with Friedreich’s ataxia</article-title>. <source>J Neurol</source>. <year>2009</year>;<volume>256</volume>(<issue>7</issue>):<fpage>1114</fpage>–<lpage>1120</lpage>.</citation>
</ref>
<ref id="bibr20-0883073812453872">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boesch</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sturm</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Hering</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Goldenberg</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Poewe</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Scheiber-Mojdehkar</surname>
<given-names>B</given-names>
</name>
</person-group>. <article-title>Friedreich’s ataxia: clinical pilot trial with recombinant human erythropoietin</article-title>. <source>Ann Neurol</source>. <year>2007</year>;<volume>62</volume>(<issue>5</issue>):<fpage>521</fpage>–<lpage>524</lpage>.</citation>
</ref>
<ref id="bibr21-0883073812453872">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boesch</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sturm</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Hering</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Neurological effects of recombinant human erythropoietin in Friedreich’s ataxia: a clinical pilot trial</article-title>. <source>Mov Disord</source>. <year>2008</year>;<volume>23</volume>(<issue>13</issue>):<fpage>1940</fpage>–<lpage>1944</lpage>.</citation>
</ref>
<ref id="bibr22-0883073812453872">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sacca</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Piro</surname>
<given-names>R</given-names>
</name>
<name>
<surname>De Michele</surname>
<given-names>G</given-names>
</name>
<etal/>
</person-group>. <article-title>Epoetin alfa increases frataxin production in Friedreich’s ataxia without affecting hematocrit</article-title>. <source>Mov Disord</source>. <year>2011</year>;<volume>26</volume>(<issue>4</issue>):<fpage>739</fpage>–<lpage>742</lpage>.</citation>
</ref>
<ref id="bibr23-0883073812453872">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nachbauer</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Hering</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Seifert</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Effects of erythropoietin on frataxin levels and mitochondrial function in Friedreich ataxia: a dose-response trial</article-title>. <source>Cerebellum</source>. <year>2011</year>;<volume>10</volume>(<issue>4</issue>):<fpage>763</fpage>–<lpage>769</lpage>.</citation>
</ref>
<ref id="bibr24-0883073812453872">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mariotti</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Fancellu</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Caldarazzo</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Erythropoietin in Friedreich ataxia: no effect on frataxin in a randomized controlled trial</article-title>. <source>Mov Disord</source>. <year>2012</year>;<volume>27</volume>(<issue>3</issue>):<fpage>446</fpage>–<lpage>449</lpage>.</citation>
</ref>
<ref id="bibr25-0883073812453872">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Armstrong</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Khdour</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Hecht</surname>
<given-names>SM</given-names>
</name>
</person-group>. <article-title>Does oxidative stress contribute to the pathology of Friedreich’s ataxia? A radical question</article-title>. <source>FASEB J</source>. <year>2010</year>;<volume>24</volume>(<issue>7</issue>):<fpage>2152</fpage>–<lpage>2163</lpage>.</citation>
</ref>
<ref id="bibr26-0883073812453872">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schmucker</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Puccio</surname>
<given-names>H</given-names>
</name>
</person-group>. <article-title>Understanding the molecular mechanisms of Friedreich’s ataxia to develop therapeutic approaches</article-title>. <source>Hum Mol Genet</source>. <year>2010</year>;<volume>19</volume>(<issue>R1</issue>):<fpage>R103</fpage>–<lpage>R110</lpage>.</citation>
</ref>
<ref id="bibr27-0883073812453872">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cotticelli</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Rasmussen</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Kushner</surname>
<given-names>NL</given-names>
</name>
<etal/>
</person-group>. <article-title>Primary and secondary drug screening assays for Friedreich ataxia</article-title>. <source>J Biomol Screen</source>. <year>2012</year>;<volume>17</volume>(<issue>3</issue>):<fpage>303</fpage>–<lpage>313</lpage>.</citation>
</ref>
<ref id="bibr28-0883073812453872">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Orsucci</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Mancuso</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ienco</surname>
<given-names>EC</given-names>
</name>
<name>
<surname>LoGerfo</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Siciliano</surname>
<given-names>G</given-names>
</name>
</person-group>. <article-title>Targeting mitochondrial dysfunction and neurodegeneration by means of coenzyme Q10 and its analogues</article-title>. <source>Curr Med Chem</source>. <year>2011</year>;<volume>18</volume>(<issue>26</issue>):<fpage>4053</fpage>–<lpage>4064</lpage>.</citation>
</ref>
<ref id="bibr29-0883073812453872">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sugiyama</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Fujita</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Matsumoto</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Okamoto</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Imada</surname>
<given-names>I</given-names>
</name>
</person-group>. <article-title>Effects of idebenone (CV-2619) and its metabolites on respiratory activity and lipid peroxidation in brain mitochondria from rats and dogs</article-title>. <source>J Pharmacobiodyn</source>. <year>1985</year>;<volume>8</volume>(<issue>12</issue>):<fpage>1006</fpage>–<lpage>1017</lpage>.</citation>
</ref>
<ref id="bibr30-0883073812453872">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hart</surname>
<given-names>PE</given-names>
</name>
<name>
<surname>Lodi</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Rajagopalan</surname>
<given-names>B</given-names>
</name>
<etal/>
</person-group>. <article-title>Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up</article-title>. <source>Arch Neurol</source>. <year>2005</year>;<volume>62</volume>(<issue>4</issue>):<fpage>621</fpage>–<lpage>626</lpage>.</citation>
</ref>
<ref id="bibr31-0883073812453872">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cooper</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Korlipara</surname>
<given-names>LV</given-names>
</name>
<name>
<surname>Hart</surname>
<given-names>PE</given-names>
</name>
<name>
<surname>Bradley</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Schapira</surname>
<given-names>AH</given-names>
</name>
</person-group>. <article-title>Coenzyme Q10 and vitamin E deficiency in Friedreich’s ataxia: predictor of efficacy of vitamin E and coenzyme Q10 therapy</article-title>. <source>Eur J Neurol</source>. <year>2008</year>;<volume>15</volume>(<issue>12</issue>):<fpage>1371</fpage>–<lpage>1379</lpage>.</citation>
</ref>
<ref id="bibr32-0883073812453872">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hausse</surname>
<given-names>AO</given-names>
</name>
<name>
<surname>Aggoun</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Bonnet</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>Idebenone and reduced cardiac hypertrophy in Friedreich’s ataxia</article-title>. <source>Heart</source>. <year>2002</year>;<volume>87</volume>(<issue>4</issue>):<fpage>346</fpage>–<lpage>349</lpage>.</citation>
</ref>
<ref id="bibr33-0883073812453872">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mariotti</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Solari</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Torta</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Marano</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Fiorentini</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Di Donato</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial</article-title>. <source>Neurology</source>. <year>2003</year>;<volume>60</volume>(<issue>10</issue>):<fpage>1676</fpage>–<lpage>1679</lpage>.</citation>
</ref>
<ref id="bibr34-0883073812453872">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Buyse</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Mertens</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Di Salvo</surname>
<given-names>G</given-names>
</name>
<etal/>
</person-group>. <article-title>Idebenone treatment in Friedreich’s ataxia: neurological, cardiac, and biochemical monitoring</article-title>. <source>Neurology</source>. <year>2003</year>;<volume>60</volume>(<issue>10</issue>):<fpage>1679</fpage>–<lpage>1681</lpage>.</citation>
</ref>
<ref id="bibr35-0883073812453872">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pineda</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Arpa</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Montero</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>Idebenone treatment in paediatric and adult patients with Friedreich ataxia: long-term follow-up</article-title>. <source>Eur J Paediatr Neurol</source>. <year>2008</year>;<volume>12</volume>(<issue>6</issue>):<fpage>470</fpage>–<lpage>475</lpage>.</citation>
</ref>
<ref id="bibr36-0883073812453872">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Di Prospero</surname>
<given-names>NA</given-names>
</name>
<name>
<surname>Sumner</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Penzak</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Ravina</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Fischbeck</surname>
<given-names>KH</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>JP</given-names>
</name>
</person-group>. <article-title>Safety, tolerability, and pharmacokinetics of high-dose idebenone in patients with Friedreich ataxia</article-title>. <source>Arch Neurol</source>. <year>2007</year>;<volume>64</volume>(<issue>6</issue>):<fpage>803</fpage>–<lpage>808</lpage>.</citation>
</ref>
<ref id="bibr37-0883073812453872">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Di Prospero</surname>
<given-names>NA</given-names>
</name>
<name>
<surname>Baker</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Jeffries</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Fischbeck</surname>
<given-names>KH</given-names>
</name>
</person-group>. <article-title>Neurological effects of high-dose idebenone in patients with Friedreich’s ataxia: a randomised, placebo-controlled trial</article-title>. <source>Lancet Neurol</source>. <year>2007</year>;<volume>6</volume>(<issue>10</issue>):<fpage>878</fpage>–<lpage>886</lpage>.</citation>
</ref>
<ref id="bibr38-0883073812453872">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lynch</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Perlman</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Meier</surname>
<given-names>T</given-names>
</name>
</person-group>. <article-title>A phase 3, double-blind, placebo-controlled trial of idebenone in Friedreich ataxia</article-title>. <source>Arch Neurol</source>. <year>2010</year>;<volume>67</volume>(<issue>8</issue>):<fpage>941</fpage>–<lpage>947</lpage>.</citation>
</ref>
<ref id="bibr39-0883073812453872">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lagedrost</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Sutton</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>MS</given-names>
</name>
<etal/>
</person-group>. <article-title>Idebenone in Friedreich ataxia cardiomyopathy: results from a 6-month phase III study (IONIA)</article-title>. <source>Am Heart J</source>. <year>2011</year>;<volume>161</volume>(<issue>3</issue>):<fpage>639</fpage>–<lpage>645</lpage>.e1.</citation>
</ref>
<ref id="bibr40-0883073812453872">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meier</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Perlman</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Rummey</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Coppard</surname>
<given-names>NJ</given-names>
</name>
<name>
<surname>Lynch</surname>
<given-names>DR</given-names>
</name>
</person-group>. <article-title>Assessment of neurological efficacy of idebenone in pediatric patients with Friedreich’s ataxia: data from a 6-month controlled study followed by a 12-month open-label extension study</article-title>. <source>J Neurol</source>. <year>2012</year>;<volume>259</volume>(<issue>2</issue>):<fpage>284</fpage>–<lpage>291</lpage>.</citation>
</ref>
<ref id="bibr41-0883073812453872">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Myers</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Farmer</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>RB</given-names>
</name>
<etal/>
</person-group>. <article-title>Antioxidant use in Friedreich ataxia</article-title>. <source>J Neurol Sci</source>. <year>2008</year>;<volume>267</volume>(<issue>1-2</issue>):<fpage>174</fpage>–<lpage>176</lpage>.</citation>
</ref>
<ref id="bibr42-0883073812453872">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Artuch</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Aracil</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mas</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Friedreich’s ataxia: idebenone treatment in early stage patients</article-title>. <source>Neuropediatrics</source>. <year>2002</year>;<volume>33</volume>(<issue>4</issue>):<fpage>190</fpage>–<lpage>193</lpage>.</citation>
</ref>
<ref id="bibr43-0883073812453872">
<label>43</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Drinkard</surname>
<given-names>BE</given-names>
</name>
<name>
<surname>Keyser</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Paul</surname>
<given-names>SM</given-names>
</name>
<etal/>
</person-group>. <article-title>Exercise capacity and idebenone intervention in children and adolescents with Friedreich ataxia</article-title>. <source>Arch Phys Med Rehabil</source>. <year>2010</year>;<volume>91</volume>(<issue>7</issue>):<fpage>1044</fpage>–<lpage>1050</lpage>.</citation>
</ref>
<ref id="bibr44-0883073812453872">
<label>44</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Velasco-Sanchez</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Aracil</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Montero</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>Combined therapy with idebenone and deferiprone in patients with Friedreich’s ataxia</article-title>. <source>Cerebellum</source>. <year>2011</year>;<volume>10</volume>(<issue>1</issue>):<fpage>1</fpage>–<lpage>8</lpage>.</citation>
</ref>
<ref id="bibr45-0883073812453872">
<label>45</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schols</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Zange</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Abele</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>L-carnitine and creatine in Friedreich’s ataxia: a randomized, placebo-controlled crossover trial</article-title>. <source>J Neural Transm</source>. <year>2005</year>;<volume>112</volume>(<issue>6</issue>):<fpage>789</fpage>–<lpage>796</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>